Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Effectiveness in Parkinson's Disease Psychosis (PDP) Symptoms: Pimavanserin demonstrated efficacy in reducing PDP symptoms, showing a mean difference of -0.5 (95% credible interval (Crl): [-0.9 to -0.2]) on the Clinical Global Impression-Severity of Illness (CGI-S) scale compared to placebo.
• Effectiveness Comparisons with Other Drugs: Clozapine showed greater efficacy than pimavanserin in treating PDP, with a mean difference of -5.6 on the Brief Psychiatry Rating Scale (BPRS) and -1.2 on the CGI-S, though it had a higher rate of adverse event-related dropouts. Safinamide significantly improved motor symptoms as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) part III, with p-values of 0.0138 and 0.0006 for 50 mg and 100 mg doses, respectively.
• Pimavanserin was associated with a higher dropout rate due to adverse events, with an odds ratio of 2.2 (95% Crl: [0.5 to 12.4]) compared to placebo, while clozapine had an even higher dropout tendency with an odds ratio of 2.9 (95% Crl: [0.9 to 9.6]).
• Both pimavanserin and clozapine showed minimal impact on motor function, with mean differences in UPDRS-III scores of 0.2 (95% Crl: [-1.4 to 1.9]) and -1.1 (95% Crl: [-3.8 to 1.5]), respectively, compared to placebo.
• There is no population types or subgroups information available in the reviewed studies.